NeoGenomics (NEO) announced the acquisition of Pathline, a CLIA/CAP/NYS-certified laboratory based in New Jersey. Founded in 2009, Pathline serves a client base of hospitals, cancer centers, and physician practices, with approximately 98% of its revenue coming from customers in the Northeast. Leveraging its differentiated commercial infrastructure, NeoGenomics expects to grow incremental topline revenue with contributions from the acquired business while operational consolidation efforts and synergies are expected to yield substantial annual cost reductions, which will be accretive to AEBITDA starting in 2026.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
- NeoGenomics price target lowered to $18 from $21 at Piper Sandler
- NeoGenomics: Strong Core Business and Growth Catalysts Justify Buy Rating Despite Challenges
- NeoGenomics price target lowered to $17 from $18 at BTIG
- NeoGenomics price target lowered to $19 from $20 at TD Cowen
- NeoGenomics price target lowered to $16 from $19 at BofA